Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 88549968

Next Previous
X
Search
Drug Profile

JNJ 88549968

Alternative Names: JNJ-88549968

Latest Information Update: 12 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Calreticulin modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myeloproliferative disorders

Most Recent Events

  • 11 Dec 2023 Phase-I clinical trials in Myeloproliferative disorders in USA (Parenteral) (NCT06150157) (EudraCT2023-505584-36-00)
  • 06 Dec 2023 Preclinical trials in Myeloproliferative disorders in USA (Parenteral)
  • 21 Nov 2023 Janssen Research & Development plans a phase I trial for myeloproliferative disorders (Parenteral) in December 2023 (NCT06150157) (EudraCT2023-505584-36-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top